Antitrust & Competition Policy Blog

Editor: D. Daniel Sokol
University of Florida
Levin College of Law

Thursday, August 5, 2010

Settlement Agreements and Patent Abuse in the Pharmaceutical Sector: An EU/US Comparison

Posted by D. Daniel Sokol

Settlement Agreements and Patent Abuse in the Pharmaceutical Sector: An EU/US Comparison 20 October 2010, The Stanhope Hotel, Brussels


The pharmaceutical sector continues to be one of the main focus areas for competition authorities throughout the world.  This conference provides an update on the major developments affecting the sector including the General Court's recent judgment in the AstraZeneca case, the first judgment on dominance and abusive practices in the pharmaceutical sector. 


Download the PROGRAMME here:


Our panel of expert speakers from both the EU and US, will provide important guidance on a number of key issues emerging from the judgment and the Commission's recent Sector Inquiry.




* Stephen Kon, Partner, SJ Berwin LLP

* Dominik Schnichels, Head of Pharma Task Force, DG Competition, European Commission

* Mike Walker, Vice President, Charles River Associates

* Marleen van Kerckhove, Partner, Arnold & Porter LLP

* Asim Varma, Partner, Arnold & Porter LLP (Washington DC)

* James S. Venit, Partner, Skadden Arps Slate Meagher & Flom LLP

* Cameron Firth, Patner, SJ Berwin LLP

* David Rosenberg, Industry Affairs Manager, Corporate IP, GlaxoSmithKline

* Gavin Robert, Partner, Linklaters LLP

* Jeffrey Schmidt, Partner, Linklaters LLP (New York)

* Melanie Thill Tayara, Partner, Norton Rose

* Jordi Faus, Partner, Faus & Moliner Abogados

* Thomas Wessely, Partner, Freshfields Bruckhaus Deringer LLP




Delegates will receive practical analysis and advice on:


* AstraZeneca and the Commission's Pharma policy

* Market definition and dominance in the Pharma sector following AstraZeneca-what does it mean for your company?

* Unilateral conduct-when does it risk infringing antitrust rules? A view from the EU and the US

* EU and US approach to settlement agreements

* Roundtable: a follow up on the EU inquiry at national level




Register before 15 September 2010 to save £100 with our early bird fees -


* Standard early bird fee: £550 + TVA (£665.50 including TVA)

* In-house lawyers and government agency early bird fee: £450 + TVA (£544.50 including TVA)


Register here:


The above early bird rates are only available until 15 September 2010




* 2010 Antitrust Litigation

12 October 2010, The King's Fund, London


* International Merger Control

A conference to mark the 20th Anniversary of the EU Merger Regulation

28 & 29 September 2010, The Radisson Blu Royal Hotel, Brussels


* GCR's 2010 Competition Law Review

In depth analysis and debate on recent developments in competition law and policy

16 & 17 November 2010, The Conrad Hotel, Brussels


* GCR's Antitrust Law Leaders Forum 2010

3 to 5 February 2010, The Fontainebleau Hotel, Miami


For further details on any of these events, please contact



Cancellations must be received in writing. Cancellations received in writing two weeks before the conference will receive a refund less 10% + TVA. Cancellations received one week before will receive a refund less 50% + TVA. Cancellations received less than a week before the conference will not receive a refund. Substitute delegates are welcome at any time.



To unsubscribe, please email with unregister in the subject field. If you have any queries regarding this briefing please contact us at


Data protection

Any personal information provided by you will be held on a database and may be shared with other Law Business Research publications. If you do not want us to use your information for marketing purposes please contact

| Permalink

TrackBack URL for this entry:

Listed below are links to weblogs that reference Settlement Agreements and Patent Abuse in the Pharmaceutical Sector: An EU/US Comparison :


Post a comment